Navigation Links
Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center
Date:8/12/2009

EMERYVILLE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that it has entered into an agreement to terminate its license and cooperation agreement with Merz Pharmaceuticals GmbH (Merz) and Children's Medical Center Corporation (CMCC). Pursuant to the termination of the agreement, within 10 business days Merz will make a final payment to NTI in satisfaction of all its royalty and other obligations under the license and cooperation agreement. Also pursuant to the termination agreement, NTI and Merz agreed to a mutual release of all claims related to the license and cooperation agreement.

NTI also announced that it received a regularly scheduled royalty payment from Merz immediately prior to entering into the termination of the license and cooperation agreement.

Under the license and cooperation agreement, as amended in 2008, NTI and CMCC have been entitled to receive quarterly royalty payments from Merz on sales of Memantine in the United States, with scheduled reductions in the royalty rates. The termination of the agreement with respect to NTI does not affect the rights and obligations flowing between Merz and CMCC under the amended agreement. The royalty payment received and the termination payment due from Merz aggregate approximately $6 million and will be recognized as revenue in the quarter ending September 30, 2010, the first quarter of NTI's 2010 fiscal year.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions. The company is currently reviewing strategic alternatives with the goal of maximizing the value of its cash and other assets for the
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
2. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
3. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies Announces Suspension of Viprinex Development
5. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
6. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
7. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
8. Neurobiological Technologies Sets Date for First Quarter Financial Results
9. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
10. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
11. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 GEA Niro Soavi the leader ... homogenizer, the PandaPLUS 2000, which is ideal for new ... cell disruption . This compact laboratory homogenizer is ... liquid food, food additives and ingredients as well as ...
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf ... portfolio of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 ... 5424/5424 R and receive the following:, , ... or Eppendorf Reference 2 ,     3 Free ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Global Compliance Service for Controlled Substances to Expand to China 2
... Company Inc. (Nasdaq: NSTK ) announced today ... of Nastech. Dr. Brandt previously,held the title of ... Steven Quay will remain the Company,s Chairman and ... Gordon to the position of President of,Nastech as ...
... Technology,Development Group Corporation (Nasdaq: CTDC, "the Company" or ... and solutions focusing on,solar energy business in China, ... its strategic plan to focus the Company,s management ... energy., On December 18, 2007, the Company ...
... CLEVELAND, OH and VANCOUVER, Dec. 20 /PRNewswire-FirstCall/ - ... Inc. (NASDAQ: ANPI, TSX:,ANP), announced today that Athersys ... Administration (FDA) to begin a Phase I clinical ... of acute myocardial,infarction (AMI). The companies believe that ...
Cached Biology Technology:Nastech Announces Promotion of Gordon Brandt, M.D. to President 2Nastech Announces Promotion of Gordon Brandt, M.D. to President 3CTDC Announces the Disposal of Non-core Business 2Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 2Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 3Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 4Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 5Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 6
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... hydrogen, produce clean water and even create energy. ... also desalinate water, be used as flexible water filtration ... made into flexible solar cells and can also double ... bacteria-killing capabilities, it can also be used to develop ...
... oil extraction from soybean seeds. It is rich in protein, ... of the seeds and dependent on the line, and can ... The study looked at the role soybeans could ... soybean lines which were high in oleic acid and protein, ...
... ANN ARBORA common test used to determine mercury exposure ... of the toxic metal released from fillings, according to ... amalgam fillings slowly release mercury vapor into the mouth. ... question of whether this exposure presents a significant health ...
Cached Biology News:NTU scientist develops a multi-purpose wonder material to tackle enviromental challenges 2NTU scientist develops a multi-purpose wonder material to tackle enviromental challenges 3NTU scientist develops a multi-purpose wonder material to tackle enviromental challenges 4Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 3
... CDX2, a member of the caudal-related homeobox ... regulates both proliferation and differentiation in intestinal ... in triggering cells towards the phenotype of ... the maintenance of the phenotype. Clone CDX2-88 ...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
Biology Products: